What is the latest market price of infliximab?

Infliximab (Infliximab) is a TNF-α inhibitor approved by many countries around the world. It has a wide range of clinical indications and is suitable for the treatment of a variety of moderate to severe chronic inflammatory diseases. It is currently approved by the State Food and Drug Administration for six major indications: Crohn's disease (CD), ulcerative colitis, rheumatoid arthritis (RA), ankylosing spondylitis, psoriasis and psoriatic arthritis, covering multiple disciplines such as gastroenterology, rheumatology and immunology, and dermatology.

From the distribution of indications, infliximab is mainly targeted at moderate to severe patients for whom traditional treatment methods are ineffective or intolerable. It can be used both to induce remission and as maintenance medication to effectively control disease activity, prevent disease progression, and reduce the risk of complications. Especially in Crohn's disease and ulcerative colitis, infliximab has become one of the preferred biological treatments and is highly respected by clinicians.

In terms of price, infliximab is currently included in China's medical insurance catalog, but the market price still varies significantly depending on the version and place of production. Taking the Chinese market as an example, the price of domestic biosimilar drugs is relatively close to the people. The price of a single drug is generally between a few thousand yuan, and the proportion of personal out-of-pocket payments after medical insurance reimbursement is significantly reduced. The price of original imported drugs such as Remicade produced by Johnson & Johnson (Janssen) is relatively high, and the price per tube may be as high as several thousand to tens of thousands of yuan. The price in overseas markets is even higher, and each box may be close to several thousand dollars.

In recent years, with the gradual launch of biosimilar drugs, the overall price of infliximab has shown a downward trend, providing patients with a more economical treatment option. Domestic generic drugs have obtained multiple authoritative certifications for their effectiveness and safety. They are almost indistinguishable from the original drugs in terms of structure, biological activity and clinical equivalence, making positive contributions to improving drug accessibility and reducing treatment burden.

Reference materials:https://www.drugs.com/infliximab.html